Share

January 17, 2023; 100 (3) Editorial

The Dilemma of the Clinical Utility of Alzheimer Biomarker Evaluation in Everyday Clinical Practice

My Favorite PETs

David Q. Beversdorf, Douglas W. Scharre
First published September 29, 2022, DOI: https://doi.org/10.1212/WNL.0000000000201478
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
168

Share

Article Information

vol. 100 no. 3 109-110
DOI: 
https://doi.org/10.1212/WNL.0000000000201478
PubMed: 
36175147
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 29, 2022
  • Accepted in final form September 13, 2022
  • First Published September 29, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. David Q. Beversdorf, MD and
    2. Douglas W. Scharre, MD
  1. David Q. Beversdorf, MD and
    2. Scientific Advisory Boards:

    1. I have been an advisor for YAMO Pharmaceuticals, Stalicla <br>Biosciences, Scioto Biosciences, Quadrant Biosciences, Impel <br>Pharmaceuticals.<br><br>I have served as DSMB Chair for 3 different federally and <br>state funded intervention trials unrelated to this work.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I have spoken in an educational symposium for Biogen.

    Editorial Boards:

    1. I am an Associate Editor for Research in Autism Spectrum <br>Disorders (paid) as well as Creativity Research Journal <br>(unpaid) and Frontiers in Psychiatry (unpaid).

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Have been compensated as a grant reviewer from multuple <br>sources (NIH, DOD) Clinical procedures or imaging studies: <br>I have served as a consultant for Best Doctors.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Received support from the American Academy of Neurology, as <br>Chair of the Animal Research Task Force, to perform a study on <br>attitudes among students towards animal research.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Douglas W. Scharre, MD
    3. Scientific Advisory Boards:

    1. (1) BrainTest - scientific advisory board, <br>(2) Acadia - scientific advisory board, <br>(3) Lilly - scientific advisory board, <br>(4) Eisai - scientific advisory board, <br>(5) Biogen - scientific advisory board, <br>(6) Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease (R01 <br>AG071151; PIs: Huntington Potter and Peter Scott Pressman); Clinical trial from <br>University of Colorado, Denver, Anschutz Medical Campus - DSMB Board <br>member, <br>(7) Veri-T: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, <br>Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy <br>Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary <br>Progressive Aphasia (svPPA) Due to Frontotemporal Lobar Degeneration With <br>TDP-43 Pathology (FTLD-TDP) (R01 AG073482; PIs: Peter Alexander Ljubenkov <br>and Adam L. Boxer); Clinical trial from UCSF Memory and Aging Center, San <br>Francisco - DSMB Board member

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) System and method for early detection of cognitive impairment using <br>cognitive test results with its behavioral metadata. AI to assess cognitive <br>impairment &#x0096; eSAGE. Scharre DW, Ning X, and Kawakami R., <br>(2) Integrating cognitive testing, EHRs and machine learning for early detection <br>of cognitive decline. Inventors: Scharre DW and Ning X.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) BrainTest, <br>(2) Vascular Scientific

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Roche,<br>(2) Biogen,<br>(3) Janssen,<br>(4) UCB Pharma,<br>(5) Precision Med,<br>(6) Avanir,<br>(7) Lilly,<br>(8) Genetech,<br>(9) InSightec,<br>(10) Eisai,<br>(11) UniQure,<br>(12) Cerevel,<br>(13) Vivoryon,<br>(14) EIP Pharma,<br>(15) Cassava,<br>(16) BioVie,<br>(17) Cognition Therapeutics,<br>(18) Cognito

    Research Support, Government Entities:

    1. (1) NIA/NIH, R01AG073113, Co-Investigator, 2021-present,<br>(2) Univ of Southern California (Prime: NIA/NIH), U19AG024904, Co-<br>Investigator, 2016-present,<br>(3) Johns Hopkins Univ (Prime: NIA), R01AG052510, Co-Investigator, 2017-<br>present,<br>(4) NIA/NIH, R01AG059861, Co-Investigator, 2018-present,<br>(5) Univ of Southern California (Prime: NIA/NIH), R01AG053798, Co-Investigator, <br>2020-present,<br>(6) NIA/NIH, R01AG069138, Co-Investigator, 2020-present,<br>(7) Vanderbilt University (Prime: NIA/NIH), R01AG062685, Co-Investigator, <br>2020-present,<br>(8) Univ of Tennessee (Prime: NIA/NIH), R01AG061325, Co-Investigator, 2021-<br>present,<br>(9) Univ of Pennsylvania (Prime: NIH), R01AG071470, Co-Investigator, 2021-<br>present,<br>(10) University of California at San Diego (Prime: NIA), 704519, Co-Investigator, <br>2021-present,<br>(11) Univ of Southern California (Prime: NIA/NIH), R01AG047992, Co-<br>Investigator, 2017-present

    Research Support, Academic Entities:

    1. (1) University of California at San Diego (Prime: Biohaven Pharmaceuticals), PO <br>#S9002155/Subk 105210250, Co-Investigator, 2018-2022,<br>(2) Univ of Southern California (Prime: Eisai Co Ltd), AHEAD 3-45, Co-<br>Investigator, 2020-present

    Research Support, Foundations and Societies:

    1. (1) Lewy Body Dementia Association<br>Royalty Payments, Technology or Inventions: <br>(1) Self Administered Gerocognitive Examination (SAGE). Test developed for use <br>in the office setting as a brief cognitive assessment instrument for Mild <br>Cognitive Impairment (MCI) and early dementia detection, Ohio State University, <br>2014-present<br>(2) BrainTest (digitally translated Self-Administered Gerocognitive Examination <br>(eSAGE)). Electronically adapted SAGE for tablet use as a brief cognitive <br>assessment instrument for Mild Cognitive Impairment (MCI) and early dementia <br>detection, Ohio State University, 2014-present

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Radiology (D.Q.B.), Neurology, and Psychological Sciences, Columbia, MO; and Department of Neurology (D.W.S.), Ohio State University, Columbus.
  1. Correspondence
    Dr. Beversdorf beversdorfd{at}health.missouri.edu

Article usage

Article usage: September 2022 to October 2023

AbstractFullPdfSource
Sep 20220032Highwire
Oct 20220064Highwire
Nov 2022001Highwire
Dec 2022001Highwire
Jan 202380214649Highwire
Feb 20231221412Highwire
Mar 20237133Highwire
Apr 20233651Highwire
May 20232912Highwire
Jun 20233620Highwire
Jul 20232310Highwire
Aug 20236410Highwire
Sep 20232101Highwire
Oct 20231412Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me